Talaris Therapeutics is a late-clinical stage biotechnology company that is developing cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The Company's proprietary technology allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs) safely from unmatched and unrelated donors, without the toxicity and risks of a traditional bone marrow transplant.
|HQ||Louisville, KY, US||Map|
|Employees (est.) (Jan 2021)||54||(+2%)|
Talaris Therapeutics total Funding
Talaris Therapeutics latest funding size
Time since last funding
|2 months ago|
Talaris Therapeutics investors
|Viking Global Investors, Longitude Capital, Blackstone, Qiming Venture Partners, Surveyor Capital|
When was Talaris Therapeutics founded?
Talaris Therapeutics was founded in 2002.
Who are Talaris Therapeutics key executives?
Talaris Therapeutics's key executives are Scott Requadt, Suzanne Ildstad and Nancy Krieger.
How many employees does Talaris Therapeutics have?
Talaris Therapeutics has 54 employees.
Who are Talaris Therapeutics competitors?
Competitors of Talaris Therapeutics include ALX Oncology, Storm Therapeutics and Actym Therapeutics.
Where is Talaris Therapeutics headquarters?
Talaris Therapeutics headquarters is located at 201 E Jefferson St #110BLouisville, Louisville.
Where are Talaris Therapeutics offices?
Talaris Therapeutics has offices in Louisville and Wellesley.
How many offices does Talaris Therapeutics have?
Talaris Therapeutics has 3 offices.
Receive alerts for 300+ data fields across thousands of companies